As the WHO delayed approval for Covaxin seeking more technical details, the All India People’s Science Network said it would deal a serious blow to India’s plans to distribute the vaccine to other countries and those traveling abroad taking Covaxin. Was.
In a statement on Wednesday, AIPSN referred to its earlier call for the disclosure of Covaxin’s trial data and said that this flawed application to WHO regulators has caused serious damage to India’s reputation “which has affected Indian science and regulatory systems”. The situation has also been maligned, which will now come under international scrutiny and suspicion.”
“Bibi applied for DCGI one of the European Union With completely insufficient data from clinical trials inviting rejection, this was followed by a behind-the-scenes backslide by the government resulting in the grant of the EUA. More detailed results of phase-3 clinical trials were then released by BB in installments, interim results two months later and full trial data in June 2021,” AIPSN said.
It said that despite criticism from scientists and others, Bharat Biotech is yet to publish the results in a peer-reviewed journal after posting a pre-publication paper.
It urged the Centre, Ministries and Departments to adhere to scientific standards for conduct and analysis of clinical trial results, publication of results in the form of peer-reviewed articles and adhere to complete transparency.
.